What is Skye Bioscience?
Skye Bioscience is a pharmaceutical company dedicated to the development of novel therapeutic molecules. Its research focuses on addressing critical unmet needs in diseases characterized by inflammatory, fibrotic, and metabolic pathways. By leveraging proprietary technologies, Skye Bioscience aims to create innovative treatments that can significantly improve patient outcomes in these challenging disease areas. The company's strategic approach involves identifying and advancing a pipeline of drug candidates with the potential for broad therapeutic application.
How much funding has Skye Bioscience raised?
Skye Bioscience has raised a total of $73.8M across 3 funding rounds:
Stock Offering
$16.6M
Share Placement
$7M
Share Placement
$50.3M
Stock Issuance/Offering (2015): $16.6M, investors not publicly disclosed
Share Placement (2020): $7M, investors not publicly disclosed
Share Placement (2024): $50.3M supported by 5AM Ventures, Driehaus Capital Management, and Ally Bridge Group
Key Investors in Skye Bioscience
5AM Ventures
5AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Driehaus Capital Management
Founded in 1982 and headquartered in Chicago, Illinois, Driehaus Capital Management is a company that provides investment management services.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm that specializes in high-impact life science innovation, managing over $6 billion in transactions since its inception in 2013. The firm operates from offices in New York and Hong Kong, focusing on both private equity and public equity strategies across the healthcare sector. Its mission is to generate superior risk-adjusted returns for investors while addressing unmet medical needs through a blend of scientific research and financial expertise. Ally Bridge Group partners with companies throughout their lifecycle, aiming to transform healthcare through diversified investments in innovative solutions.
What's next for Skye Bioscience?
With the recent influx of major strategic investment, Skye Bioscience is poised for an accelerated growth phase. This capital will likely be deployed to advance its pipeline of proprietary molecules through critical preclinical and clinical development stages. The company's focus on inflammatory, fibrotic, and metabolic conditions positions it within key therapeutic markets. Future developments may include strategic partnerships, expanded research initiatives, and the progression of its lead candidates towards regulatory submission, aiming to bring transformative therapies to patients.
See full Skye Bioscience company page
